Novartis’s Inclisiran Unscathed As Arrowhead Falls Short
But NASH Candidate Generates Interest
Arrowhead’s drug has failed to match performance, but its RNAi platform has other promising candidates.
You may also be interested in...
Investment from Janssen helps to validate the platform developed by the San Diego-based company.
Non-profit approach is reassuring for healthcare payers, but vaccines won’t be ready to stop pandemic at its peak.
Company suspends enrolment to trials as coronavirus travel restrictions bite.